VYGR

Voyager Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 2/10
  • Value↓ 0/10
Voyager Therapeutics sales and earnings growth
VYGR Growth
Fair
  • Revenue Y/Y↓ -45.50%
  • EPS Y/Y↓ -34.69%
  • FCF Y/Y↓ -13.98%
Voyager Therapeutics gross and profit margin trends
VYGR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -319.60%
  • ROIC 5Y↓ 41.98%
Voyager Therapeutics net debt vs free cash flow
VYGR Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Voyager Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks